Perspectives from the Industry
In 2017, the global plasma protein therapy market was worth USD 22.5 billion, and it is expected to grow at a CAGR of 4.8 percent over the forecast period. The market is expected to develop because to the approval of plasma products across many indications, increased R&D activity, and a strong demand for innovative treatment choices.
Plasma proteins are commonly employed in replacement therapy to treat disorders like coagulation factor deficiency in the field of hemostasis. This deficit can be hereditary or the result of an autoimmune disease. It can also happen as a side effect of cancer treatment. In illnesses like dysfibrinogenemia, afibrinogenemia, and hypofibrinogenemia, fibrinogen is utilised as a replacement therapy to alleviate hemorrhagic diathesis.
The market penetration of plasma proteins is predicted to expand as new products with clinical benefits such as better efficacy and simple sample plasma extraction techniques are developed. Over the forecast period, the market is expected to be driven by strong demand for albumin in Asia Pacific and greater volumes of immunoglobulin usage in developed countries.
Manufacturers are focusing on innovation to develop plasma-derived products for the treatment of neuropathic pain, Myasthenia gravis, and post-polio syndrome, among other neurological illnesses. Albumin is also being tested in clinical trials to treat liver illness, malaria, sepsis, and Alzheimer’s disease. Furthermore, the greater doses required for subcutaneous immunoglobulin use are expected to drive development in developed economies like the United States, where the annual cost of Subcutaneous Immunoglobulin (SCIG) treatment is around USD 40,000.
The plasma protein therapies market is divided into albumin, immunoglobulins (IG), plasma-derived factor VIII, and others, depending on the product. Immunoglobulin was the market leader in 2017, with a market share of about 45.0 percent. The high percentage can be linked to biologics’ approval across numerous indications, simplicity of administration, and treatment cost.
Because of improved detection of hypoalbuminemia caused by liver cirrhosis and hepatitis B, the albumin segment is predicted to gain considerable market share throughout the projection period. High demand and usage in China, the world’s largest market for albumin, are expected to fuel additional expansion. Clotting factor VIII is required as a prophylactic or on-demand medication for patients with moderate to severe haemophilia A. 70.0 percent of haemophilia patients, on the other hand, receive no or insufficient treatment. Due to increased competition from recombinant and other long-term therapy, revenues of factor VIII are likely to fall.
Alpha-1 antitrypsin, hyperimmune immunoglobulins, coagulation factors, fibrogammin, and c1 esterase inhibitors are included in the others category. The replacement therapy Alpha-1 Antitrypsin (AAT) is used to treat a rare form of hereditary emphysema. Chronic obstructive pulmonary disease (COPD), bronchitis, and newborn hepatitis are all symptoms of the insufficiency. Currently, only roughly 10.0 percent to 15.0 percent of AAT deficient individuals in the United States and Europe receive treatment, leaving possibility for market expansion. Improvements in diagnostic rates and product introductions are expected to foster profitable growth in the entire segment.
Insights into the Application
Hemophilia, Primary Immunodeficiency Diseases (PID), Idiopathic Thrombocytopenic Purpura (ITP), and other diseases are among the applications for plasma protein therapies. More than 200 rare, chronic disorders caused by immune system defects are classified as primary immunodeficiency diseases.
More than 6.0 million people worldwide suffer from a PID, with less than 60,000 instances recorded each year. In 2017, the PID segment had the biggest market share, and it is predicted to rise significantly over the forecast period. The category is growing due to the increasing expansion of immunoglobulin clinical uses, approval of SCIGs, and high treatment costs.
The market is divided into five regions: North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. North America and Europe account for around 70.0 percent of the market. In 2017, the United States led the market with a 40.0 percent share. Some of the significant geographical drivers include the presence of a large patient base, a growing geriatric population, and the availability of well-developed infrastructure for storing and keeping high-quality source plasma. Other significant elements driving regional growth are increased acceptance of innovative treatments and rising disease prevalence.
During the projected period of 2018 to 2025, Asia Pacific is expected to have the highest CAGR. China leads the global albumin market, owing to the country’s significant demand and utilisation of the substance. Furthermore, factors such as rising demand for sophisticated treatment alternatives, growing economies, and rising per capita income are expected to provide development opportunities for emerging market players over the projection period.
Insights into the Market for Plasma Protein Therapeutics
CSL Behring LLC, Octapharma AG, Grifols S.A., Shire Plc, Bayer AG, Biotest AG, and Kedrion S.P.A. are some of the major companies. In 2017, CSL Behring LLC dominated the plasma proteins market, with over 20.0 percent of the market share. Hizentra, CSL’s first and only subcutaneous immunoglobulin therapy for Chronic Inflammatory Demyelinating Polyneuropathy, was authorised by the Food and Drug Administration (FDA) in March 2018. (CIDP). The company’s market supremacy is supported by a differentiated product profile, dominance in China, the biggest number of plasma donor centres, and substantial fractionation capacity.
With competitors focusing on novel drug discovery and extending plasma collection networks, the market is projected to stay competitive. Grifols S.A. purchased 24 plasma donor centres in the United States from Biotest AG in August 2018. Companies are concentrating on alliances to expand their product line and geographical presence, as well as clinical trials to boost market share. Shire Plc paid USD 32.0 billion for Baxalta, a spin-off biopharmaceutical division of Baxter Inc., in June 2016. Shire acquired Baxalta’s pharmaceutical portfolio as well as a strong pipeline for the treatment of rare diseases, according to the agreement.
The Report’s Covered Segments
From 2014 through 2025, this research projects revenue growth at the global, regional, and country levels, as well as an analysis of the most recent industry trends in each of the sub-segments. Grand View Research has segmented the global plasma protein therapies market research by product, application, and geography for the purposes of this study.
Read also:Saturated Polyester Resin Market